The Top 5 Biosimilars Articles for the Week of November 11

November 15, 2019

The Center for Biosimilars® recaps the top stories for the week of November 11, 2019.

Transcript

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 11, 2019.

Number 5: A new study shows the extent to which financial hardship is impacting seriously ill Medicare beneficiaries.

Number 4: During the FT Global Pharmaceutical and Biotechnology Conference, Celltrion gave a look at its plans for CT-P13.

Number 3: Prescription drug prices are now front and center in the push to make health insurance coverage more affordable to provide to American workers.

Number 2: Price hikes alone accounted for most recent spending growth on biologics, according to research presented at the American College of Rheumatology’s 2019 annual meeting.

Number 1: On Monday, the first biosimilar rituximab began to reach US oncology patients.

Finally, last week, our e-newsletter asked whether you are optimistic that Stephen Hahn, MD, will be proactive about biosimilars if he is confirmed as the next FDA Commissioner.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.